Study protocol for a phase 1/2, single-centre, double-blind, double-dummy, randomized, active-controlled, age de-escalation trial to assess the safety, tolerability and immunogenicity of a measles and rubella vaccine delivered by a microneedle patch in healthy adults (18 to 40 years), measles and rubella vaccine-primed toddlers (15 to 18 months) and measles and rubella vaccine-naïve infants (9 to 10 months) in The Gambia (2022)

First Author: Adigweme I

Attributed to: Clinical Services Department funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1186/s13063-022-06493-5

PubMed Identifier: 36104719

Publication URI: http://europepmc.org/abstract/MED/36104719

Type: Journal Article/Review

Volume: 23

Parent Publication: Trials

Issue: 1

ISSN: 1745-6215